Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 ...
The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine ... and have large negative effects on patient quality of life, so new therapies ...
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...
Those on Spravato experienced a significant and sustained reduction in depression symptoms compared to controls, the study found. Only 7.6% of patients taking a placebo experienced a clear ...
"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not respond to ...
For too long, healthcare providers have had few options to offer patients' much-needed symptom improvement," said Bill Martin, J&J's global therapeutic area head for neuroscience. "Spravato is now ...